Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
نویسندگان
چکیده
منابع مشابه
Update on Cholinesterase Inhibitors and Treatment of Alzheimer’s Disease
The long-term studies of the cholinesterase inhibitors, Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine), support their ability to delay Alzheimer’s disease (AD) progression during the dementia stage by 1, 1.5, and 2.5 years respectively, which underscores the importance of early detection to optimize quality of life. Cholinesterase inhibitors reduce caregiving burden by de...
متن کاملCholinesterase inhibitors in the treatment of dementia.
Dementia associated with probable Alzheimer's disease (AD) is one of the most common types of dementia. Patients with AD often have cholinergic deficits in association with the disease. The cholinesterase inhibitors donepezil hydrochloride, galantamine hydrobromide, and rivastigmine tartrate are the current mainstays of symptomatic treatment for patients with AD. In clinical trials for all thre...
متن کاملCholinesterase Inhibitors: Drugs Looking for a Disease?
0456 R andomized controlled trials (RCTs) are generally considered to be a robust form of evidence, free from bias, and the trial results are often used as a powerful tool to promote new drugs [1,2]. However, because the inclusion criteria for many RCTs are often very restrictive (for example, trials generally exclude patients with serious concomitant illnesses) and because patients in trials t...
متن کاملGlucose Role in Treatment of Alzheimers’ Disease
1. Dong H, Csernansky JG (2009) Effects of Stress and Stress Hormones on Amyloidβ Protein and Plaque Deposition. J Alzheimers Dis 18: 459-469. 2. Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, et al. (2006) Plasma cortisol and progression of dementia in subjects with Alzheimer‐ type dementia. Am J Psychiatry 163: 2164-2169. 3. Swaab DF, Raadsheer FC, Endert E, Hofman MA, Kamphorst W, et al. ...
متن کاملQSAR Models towards Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease
Alzheimer’s Disease (AD) is a multifactorial neurological syndrome with the combination of aging, genetic, and environmental factors triggering the pathological decline. Interestingly, the importance of the Acetylcholinesterase (AChE) enzyme has increased due to its involvement in the β-amyloid peptide fibril formation during AD pathogenesis. In silico technique, QSAR has proven its usefulness ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Therapeutic Research
سال: 2003
ISSN: 0011-393X
DOI: 10.1016/s0011-393x(03)00059-6